Komori et al. found that the level of CHI3L1(YKL40) in CSF was significantly reduced in multiple sclerosis patients receiving daclizumab, and the inhibition of CHI3L1(YKL40) was correlated with the inhibition of NFL and a lack of disease progression [70]. Here, CHI3L1 is linked to multiple sclerosis.